SBC at a glance
SBC Medical Group Holdings Inc (SBC, SEC CIK 1930313) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and Form 4 insider filings as recently as April 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), SBC Medical Group Holdings Inc (SBC) reported revenue of $173.6 million (down 15.5% from FY2024) and net income of $51.0 million. Diluted EPS was $0.50.
- As of June 30, 2026, 16 institutional investment managers tracked by SignalX reported holding SBC Medical Group Holdings Inc (SBC) shares worth $5.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Aikawa Yoshiyuki on April 28, 2026 of 465,000 shares at $3.02 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $173.6M
- −15.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 16 funds
- $5.1M · +2 vs prior quarter
- Latest 8-K
- Aug 13, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $49.2M, up from $43.4M YoY
- Quarterly net income $10.7M, up from $2.5M YoY
- Six-month operating cash flow $31.7M vs $(6.4)M YoY
- Outlook: strengthening Shonan Beauty Clinic brand across Japan, Vietnam, Singapore and globally
Risk Factors
- Newly disclosed Nasdaq compliance risk triggered by director non-re-election on July 8, 2026
- Nasdaq cure period through July 9, 2027, or January 5, 2027 if the annual meeting occurs earlier
- Delisting risk could reduce securities liquidity and restrict future financing access
- Governance compliance risk from board independence and audit committee size requirements under Listing Rule 5605
- No material liquidity, debt maturity, currency, or concentration risks disclosed in provided section
AI summary of the SBC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results released August 13, 2026
- Press release contains the financial results and operating commentary
Item 7.01: Regulation FD Disclosure
- 2Q 2026 investor presentations posted August 13, 2026
- Materials cover business overview and results for quarter ended June 30, 2026
Item EX-99.1: Item EX-99.1
- Q2 revenue $49M, up 13% YoY, signaling growth reacceleration after 2025 restructuring
- Net income attributable to SBC Medical $11M, up 335%, with margin expanding to 22% from 6%
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Nasdaq noncompliance triggered by Mike Sayama’s departure from the Board and Audit Committee
- Board now four members, with two independent directors; Audit Committee has two independent members
Item 5.07: Submission of Matters to a Vote of Security Holders
- 93,987,291 shares represented, establishing a strong quorum against 102,576,943 shares entitled to vote
- All four director nominees elected through the 2027 annual meeting, with 89,910,053–90,426,406 votes supporting
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Independent director Mike Sayama will not seek re-election at the 2026 AGM
- Board size reduced to four members effective immediately before 2026 AGM polls open
AI summaries of SBC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SBC
Don't miss the next SBC filing
- Alerts as it files. A push when SBC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SBC, by share count.
- Ask anything. An AI agent that reads every SBC filing and answers with sources.
SBC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Aikawa Yoshiyuki | Sell | Apr 28, 2026 | 465,000 | $3.02 |
| Aikawa Yoshiyuki | Sell | Apr 21, 2026 | 3,100,000 | $3.02 |
| Aikawa Yoshiyuki | Sell | Mar 6, 2026 | 4,422,900 | $2.12 |
| Aikawa Yoshiyuki | J | Mar 6, 2026 | 44,229 | - |
| Aikawa Yoshiyuki | J | Mar 6, 2026 | 44,229 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $205.4M | $173.6M |
| Gross Profit | - | $156.1M | $127.3M |
| Operating Income | - | $70.3M | $67.5M |
| Net Income | - | $46.6M | $51.0M |
| Gross Margin | - | 76.0% | 73.3% |
| Op. Margin | - | 34.2% | 38.9% |
| Net Margin | - | 22.7% | 29.4% |
| Balance Sheet | |||
| Total Assets | - | $266.1M | $380.4M |
| Equity | -$6.0M | $195.1M | $248.3M |
| ROE | - | 23.9% | 20.5% |
| Per Share | |||
| EPS | $0.42 | $0.48 | $0.50 |
| Cash Flow | |||
| Operating CF | - | $20.6M | $24.7M |
| CapEx | - | $2.6M | $1.4M |
Source: XBRL data in SBC Medical Group Holdings Inc (SBC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SBC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 16 | $5.1M |
| Q1 2026 | 14 | $3.4M |
| Q4 2025 | 13 | $3.8M |
| Q3 2025 | 12 | $2.3M |
| Q2 2025 | 11 | $1.9M |
| Q1 2025 | 1 | $3,000 |
- BlackRock+504.4K (+120%)
- Vanguard Portfolio Management LLC+64.7K (+102%)
- Northern Trust+40.1K (+44%)
- State Street Corp+18.4K (+60%)
- BNY Mellon+16.8K (+165%)
- Vanguard Capital Management LLC−456 (-0%)
- Citadel Advisors LLC+144.7K
- Bank of America Corp+11.4K
- T. Rowe Price Group+11.1K
- Goldman Sachs Group−25.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 67 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SBC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 29, 2026 | - | - | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 4 | Apr 23, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
| 10-K | Mar 27, 2026 | Dec 31, 2025 | - | |
| SC 13G | Mar 13, 2026 | - | - | |
| 4 | Mar 10, 2026 | - | - | - |
| 8-K | Jan 5, 2026 | - | - | |
| 8-K | Dec 31, 2025 | - | - | |
| 8-K | Dec 15, 2025 | - | - | |
| 10-Q | Nov 14, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 13, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 15, 2025 | Mar 31, 2025 | - | |
| 10-K | Mar 28, 2025 | Dec 31, 2024 | Analysis | |
| 10-Q | Nov 13, 2024 | Sep 30, 2024 | - | |
| SC 13D | Sep 23, 2024 | - | - | |
| 10-Q | Aug 16, 2024 | Jun 30, 2024 | - | |
| 10-Q | May 20, 2024 | Mar 31, 2024 | - | |
| 10-K | Mar 19, 2024 | Dec 31, 2023 | - |
Related Health Care companies
- AIRS · Airsculpt Technologies, Inc.Services-Offices & Clinics of Doctors of Medicine
- HIMS · Hims & Hers Health, Inc.Services-Offices & Clinics of Doctors of Medicine
- LFMD · LifeMD, Inc.Services-Offices & Clinics of Doctors of Medicine
- TOI · Oncology Institute, Inc.Services-Offices & Clinics of Doctors of Medicine
- TDOC · Teladoc Health, Inc.Services-Offices & Clinics of Doctors of Medicine
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
SBC SEC filings: frequently asked questions
Which institutions hold SBC stock?
As of June 30, 2026, the largest SBC Medical Group Holdings Inc (SBC) holders among the 13F filers tracked by SignalX were BlackRock ($2.8 million), Citadel Advisors LLC ($445,000), Vanguard Capital Management LLC ($418,000), Northern Trust ($404,000), Vanguard Portfolio Management LLC ($395,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SBC's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), SBC Medical Group Holdings Inc (SBC) reported revenue of $173.6 million (down 15.5% from FY2024) and net income of $51.0 million. Diluted EPS was $0.50. The figures come from the XBRL data in the 10-K.
What did SBC report in its latest 8-K?
SBC Medical Group Holdings Inc (SBC) filed an 8-K on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Fiscal quarter ended June 30, 2026 results released August 13, 2026.
What are the latest SBC SEC filings?
SBC Medical Group Holdings Inc (SBC) filed its latest 10-K annual report on March 27, 2026, a 10-Q quarterly report on August 13, 2026, an 8-K current report on August 13, 2026 and a Form 4 insider filing on April 29, 2026.
What is SBC's SEC CIK number?
SBC Medical Group Holdings Inc (SBC)'s SEC Central Index Key (CIK) is 1930313. EDGAR lists every SBC filing under that number.
Ask anything about SBC
The research agent reads SBC's filings, financials, insider trades and 13F holders, then answers with sources.